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Treatment outcomeAbstract Purpose: This review provides a description of the epidemiology and survival out-
comes for cases with metastatic basal cell carcinoma (mBCC) based on published reports
(1981–2011).
Methods: A literature search (MEDLINE via PubMed) was conducted for mBCC case reports
published in English: 1981–2011. There were 172 cases that met the following criteria: primary
BCC located on skin, metastasis conﬁrmed by pathology and metastasis not resulting from
direct tumour spread. From these, 100 mBCC cases with explicit information on follow-up
time were selected for analysis. Survival analysis was conducted using Kaplan–Meier methods.
Results: Among 100 mBCC cases selected for analysis, including one case with Gorlin syn-
drome, 50% had regional metastases (RM) and 50% had distant metastases (DM). Cases with
DM were younger at mBCC diagnosis (mean age, 58.0 versus 66.3 years for RM; P = 0.0013).
Among 93 (of 100) cases with treatment information for metastatic disease, more DM cases
received chemotherapy (36.2% versus 6.5% for RM), but more RM cases underwent surgery
(87.0% versus 40.4% for DM). Among all 100 cases, median survival after mBCC diagnosisic basal
M. McCusker et al. / European Journal of Cancer 50 (2014) 774–783 775was 54 months (95% conﬁdence interval (CI), 24–72), with shorter survival in DM (24 months;
95% CI, 12–35) versus RM cases (87 months; 95% CI, 63–not evaluable).
Conclusion: Cases with RM and DM mBCC may have different clinical courses and out-
comes. Based on published reports, DM cases were younger at mBCC diagnosis, with shorter
median survival than RM cases. This study provides a historical context for emerging mBCC
treatments.
 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-ND license. 1. Introduction
Basal cell carcinoma (BCC) is the most commonly
diagnosed skin cancer. Although most BCCs are indo-
lent, metastases occur in rare cases [1,2]. Because meta-
static BCC (mBCC) is uncommon, its incidence and
disease course are poorly characterised. Since the ﬁrst
description by Beadles [3] of mBCC in 1894, fewer than
400 cases have been reported [2]. Estimates of mBCC
incidence vary widely, ranging from 0.0028% to 0.55%
of all BCCs [2,4].
Metastatic BCC spreads by lymphatic and haematog-
enous routes [2,5,6]. For cases with lymph node metasta-
ses only, average survival is reported to be 3.6 years
after metastatic diagnosis [2]. Among cases with hae-
matogenous spread to sites such as bone, liver and lung,
average survival is reported to be 8–14 months [5,6].
Most articles describing mBCC cases cite criteria pro-
posed by Lattes and Kessler [7] (1951) to deﬁne true
mBCC cases: primary BCC located on skin, not a
mucous membrane; primary tumour described as BCC
with histological conﬁrmation of metastasis; and direct
spread of primary tumour ruled out. These criteria have
been used historically to distinguish mBCC cases from
second primary tumours and locally advanced BCC.
The emergence of novel therapies to treat metastatic
or locally advanced BCC marks the beginning of a
new era in treatment options for patients and under-
scores the need to understand disease characteristics
and course [8]. To that end, this report provides a com-
prehensive analysis of mBCC cases reported after the
von Domarus and Stevens [6] 1984 review of 170 previ-
ously published cases. The objective of this analysis is to
describe the association between the extent of disease
spread and survival among mBCC cases reported from
1981 to 2011.
2. Methods
A PubMed-based search of the MEDLINE database
identiﬁed 1016 English-language mBCC case reports
published from January 1981 to October 2011 using
the terms ‘basal cell’ or ‘basal cell carcinoma’; ‘meta-
static’, ‘metastases’ or ‘metastasis’ and ‘skin’. Articles
were manually searched to identify mBCC cases based
on the criteria by Lattes and Kessler [7]. Publications
were also identiﬁed from article bibliographies in aneﬀort to include all relevant sources. Meeting abstracts
were excluded because the analysis required detailed
information about individual cases, both to determine
survival and to conﬁrm mBCC diagnosis, which was
typically not available from abstracts.
Date of metastasis was deﬁned for each case by the
authors of the primary publications. In some cases, the
diagnosis was incidental; in others, the diagnosis
occurred as a part of routine follow-up. The diﬀerences
between cases in how the metastatic diagnosis was made
may aﬀect the survival estimates and reﬂect how mBCC
cases are likely to be diagnosed in routine clinical
practice.
To determine survival after mBCC diagnosis, either
total duration of follow-up reported in months or years
or chronologic information suﬃcient to calculate total
follow-up time after mBCC diagnosis was abstracted
for each case. For cases with chronologic information
only, month and year of mBCC diagnosis were sub-
tracted from month and year of death or last known fol-
low-up to determine total survival time. Cases were
excluded for which only year was stated for date of met-
astatic diagnosis, death or last reported follow-up.
Most cases with lymph node spread lacked suﬃcient
information on size of lymph node metastasises to apply
speciﬁc staging criteria. Instead, cases were categorised
based on extent of disease spread as either regional
metastases (RM) or distant metastases (DM). These cat-
egories were intended to align with tumour staging sys-
tems that diﬀerentiate RM from DM based on current
understanding of cancer biology. RM cases had spread
to regional lymph nodes, soft tissue (including
subcutaneous tissue or skin), salivary glands or ipsilat-
eral muscle in the same anatomic region (e.g. head and
neck primary and metastasis). DM cases had spread to
distant lymph nodes, viscera, bone, brain or meninges.
A consort diagram of mBCC cases assessed for inclusion
in survival analysis is provided in supplemental Fig. 1.
Anatomic location of the primary tumour was classi-
ﬁed into ﬁve categories: head and neck, trunk, genitals,
limbs and multiple locations. Tumours located on the
shoulder, axilla, back, chest or abdomen were classiﬁed
as trunk. Cases with two or more primary sites were
included in the multiple-locations category.
Histology descriptions were recorded for both pri-
mary tumour and metastasis. Cases without speciﬁc his-
tology details were classiﬁed as BCC. Cases with
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egory as basosquamous and metatypical tumours.
Disease characteristic diﬀerences between groups
(RM versus DM) were assessed with t tests and v2 tests.
Kaplan–Meier estimates of 1-year survival probability,
median survival time and 95% conﬁdence intervals
(CIs), were provided. Overall survival diﬀerences by site
of spread, age (<65 versus P65 years), sex, publication
date (1981–1990, 1991–2000 and 2001–2011) and treat-
ment (chemotherapy, radiation therapy or surgery) were
evaluated with the log-rank test. Data were analysed
with JMP (version 9.0; Cary, NC) and validated with
SAS (version 9.2; Cary, NC). Alpha was set at 0.05,
and all P values were two sided.3. Results
From 172 mBCC cases published from January 1981
through October 2011 that met initial evaluation crite-
ria, 100 cases with clear survival information after met-
astatic diagnosis were included in the analysis [4,6,9–90].
Sixty cases were reported from North America, 20 from
Europe, 10 from Asia, seven from Australia and NewTable 1
Selected characteristics of mBCC cases reported in the literature by site of
Characteristic All cases (n = 100) Distant m
Age at BCC diagnosis, yearsa
Mean (SE) 57.1 (1.8) 53.6 (2.1)
Median 58.0 54.5
Years from BCC to mBCC diagnosisb
Mean (SE) 8.0 (0.8) 7.4 (1.1)
Median 6.0 6.0
Age at mBCC diagnosis, years
Mean (SE) 62.1 (1.3) 58.0 (1.7)
Median 62.0 58.5
Sex
Female 31 (31.0) 14 (28.0)
Male 69 (69.0) 36 (72.0)
Location of primary BCC
Head and neck 56 (56.0) 30 (60.0)
Trunk 26 (26.0) 15 (30.0)
Genitals 7 (7.0) 2 (4.0)
Limbs 5 (5.0) 1 (2.0)
Multiple locations 6 (6.0) 2 (4.0)
Vital status at last follow-up
Alive 52 (52.0) 15 (30.0)
Dead 48 (48.0) 35 (70.0)
Treatment for metastasesc n = 93 n = 47
Chemotherapy 20 (21.5) 17 (36.2)
Radiation therapy 40 (43.0) 20 (42.6)
Surgery 59 (63.4) 19 (40.4)
None 16 (17.2) 13 (27.7)
All data are n (%) unless stated otherwise.
BCC, basal cell carcinoma; mBCC, metastatic basal cell carcinoma; SE, st
a n = 79.
b n = 95.
c n = 36 cases received >1 type of treatment.Zealand, two from Africa and one from South America.
Among 50 cases for whom race was reported, 43 (86%)
were Caucasian. Among seven cases with both mBCC
and Gorlin syndrome identiﬁed during this time period,
one had suﬃcient survival information to be included in
this analysis [12,91–96].
Table 1 shows selected characteristics for the 100
mBCC cases by site of disease spread. Nine cases had
metastases to more than two locations. Among RM
cases, one had spread to three sites (auditory meatus,
oral cavity and subcutaneous neck) [49]. Four DM cases
had metastases to three sites, and four had spread to
four sites. There was no signiﬁcant diﬀerence in time
from primary BCC to mBCC diagnosis between RM
and DM cases.
Among 93 cases with clear documentation of treat-
ment for metastases, 36 (39%) received more than one
type of treatment. Among 20 cases who received chemo-
therapy, 12 (60%) received more than one chemotherapy
agent; cases were treated with a median of two agents
(Table 2). Four cases who received chemotherapy had
no evidence of disease after treatment, three had stable
disease, 11 had progressive disease or recurrence, onedisease spread, 1981–2011.
etastases (n = 50) Regional metastases (n = 50) P value
61.1 (2.8) .037
65.0
8.6 (1.2) .48
6.0
66.3 (1.8) .0013
69.0
.52
17 (34.0)
33 (66.0)
.32
26 (52.0)
11 (22.0)
5 (10.0)
4 (8.0)
4 (8.0)
<.0001
37 (74.0)
13 (26.0)
n = 46
3 (6.5) .0005
20 (43.5) .93
40 (87.0) <.0001
3 (6.5) .0069
andard error.
Table 2
Treatment administered to mBCC patients who received chemother-
apy (n = 20),a 1981–2011.
Drug/Drug class n %
Platinum-based 16 80
Bleomycin 7 35
5-Fluorouracil 6 30
Methotrexate 4 20
Doxorubicin 3 15
Vincristine/vinblastine 2 10
Taxane 2 10
Other/unspeciﬁedb 6 30
mBCC, metastatic basal cell carcinoma.
a Twelve of 20 (60%) received >1 type of chemotherapy.
b Other drugs were amygdalin, cyclophosphamide, etoposide, gem-
citabine and rituximab. Drug was unspeciﬁed for one case.
Table 3
Histology of primary BCC in mBCC cases, 1981–2011.
Histology All
cases,
n (%)
(n = 100)
Distant
metastases,
n (%)
(n = 50)
Regional
metastases,
n (%)
(n = 50)
Basosquamous or
metatypicala
10 (10.0) 6 (12.0) 4 (8.0)
Inﬁltrativeb 14 (14.0) 9 (18.0) 5 (10.0)
Morpheaformc 10 (10.0) 5 (10.0) 5 (10.0)
Otherd 14 (14.0) 6 (12.0) 8 (16.0)
BCC, no subtype speciﬁed 52 (52.0) 24 (48.0) 28 (56.0)
BCC, basal cell carcinoma; mBCC, metastatic basal cell carcinoma.
a One case described as metatypical and morpheaform.
b Two cases described as inﬁltrative and nodular.
c One case described as morpheaform and nodular.
d Other histologies: adenoid, adenoid cystic and keratotic, clear cell,
keratotic, nodular and solid.
Table 4
Metastases by site of disease spreada for mBCC cases, 1981–2011.
Site of metastases All
cases,
n (%)
(n = 100)
Distant
metastases,
n (%)
(n = 50)
Regional
metastases,
n (%)
(n = 50)
Lymph nodes 54 (54.0) 15 (30.0) 39 (78.0)
Lung 28 (28.0) 28 (56.0) 0 (0.0)
Bone or bone
marrow
24 (24.0) 24 (48.0) 0 (0.0)
Skin or soft tissue 11 (11.0) 2 (4.0) 9 (18.0)
Salivary gland 7 (7.0) 2 (4.0) 5 (10.0)
Liver 4 (4.0) 4 (8.0) 0 (0.0)
Otherb 6 (6.0) 6 (12.0) 0 (0.0)
mBCC, metastatic basal cell carcinoma.
a Cases with metastases to >1 site are counted more than once; 25
cases had metastases to >1 site.
b Other sites include dura/meninges, kidney, mediastinum, pericar-
dium and pleura.
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Details for these cases are provided in the supplemental
Table 1.
Table 3 shows the distribution of RM and DM cases
by histology. Forty-eight cases had detailed histology
information for primary BCC and 38 cases had informa-
tion on mBCC histology. Seventy-seven cases had the
same histology description for primary tumour and
mBCC both (of which 31 were the same named histolog-
ical subtype) and 16 cases had a histology description
for the primary tumour but not for mBCC. Diﬀerences
in site of spread or survival based on histology could
not be adequately assessed because 52% of cases lacked
speciﬁc histology descriptions. Details for all cases are
provided in supplemental Table 2.
Twenty-ﬁve mBCC cases had metastases to more
than one location (Table 4). Among 24 cases with bone
metastases, 20 had disease spread to vertebrae and nine
had spread to ribs. All bone metastases were described
as being distant from the primary BCC site and were
not thought to be tumour invasion.
Among 15 DM cases with lymph node spread, 14 of
15 (93%) involved regional lymph nodes and a distantsite such as bone or lung; one case had spread to distant
lymph nodes only. Lymph node spread was described
before diagnosis of distant metastases in seven of 15
cases (47%). Four of seven cases had detailed informa-
tion on time from discovery of lymph node spread to
diagnosis of distant metastases, with a mean of
18 months (range, 11–30 months). For these four cases,
time from diagnosis of distant metastasis was used to
determine survival time.
In 33 of 35 DM cases who died, cause of death was
related to mBCC. In the remaining two DM cases who
died, one was reported as having died from another
cause, and cause of death was unknown for the other.
Among 13 RM cases who died, cause of death was
related to mBCC in ﬁve. In the other eight RM cases
who died, four died from other causes, and cause of
death was unknown for four.
Compared with RM cases, DM cases had shorter sur-
vival times, with a 1-year survival probability of 58.6%
(95% CI, 44.6–72.6%) versus 87.8% (95% CI, 78.6–
97.0%) for RM (Table 5). Median survival was
24 months among DM cases versus 87 months for RM
(Fig. 1). A sensitivity analysis that used time from lymph
node metastasis instead of time from distant metastasis
for four DM cases with this information showed no
impact on median survival, which remained at
24 months for DM. In this sensitivity analysis, the 1-
year survival probability for DM cases was slightly
higher at 63.1% (95% CI, 49.5–76.7%), but remained sig-
niﬁcantly shorter than for RM cases (P = 0.0011).
Additional survival estimates were performed to
determine whether other factors were related to mBCC
survival time. DM cases with and without bone and lung
metastases were compared because these were the two
most common sites of distant metastases. Among 24
DM cases with bone metastases, median survival was
12 months (95% CI, 5–24 months), which was signiﬁ-
cantly shorter than median survival for the 26 cases
Table 5
Kaplan–Meier estimates of 1-year and median survival by selected characteristics among mBCC cases, 1981 to 2011.
Characteristic n 1-year survival probability, % (95%
CI)
Median survival (95% CI),
months
Survival time range,
months
P
valuea
All cases 100 73.2 (64.4–82.0) 54 (24-72) 0–120+
Site of spread
Distant metastases 50 58.6 (44.6–72.6) 24 (12–35) 0–108 .0006
Regional metastases 50 87.8 (78.6–97.0) 87 (63–NE) 0–120+
Treatment (n = 93)
Chemotherapy 20 69.3 (48.8–89.8) 30 (10–54) 2–66 .12
No chemotherapy 73 76.4 (66.5–86.2) 72 (24–87) 0–120+
Radiation therapy 40 87.5 (77.2–97.8) 54 (24–76) 6–120+ .19
No radiation
therapy
53 65.2 (52.1–78.3) 87 (18–87) 0–87
Surgery 59 93.1 (86.5–99.6) 72 (63–96) 1–120+ <.0001
No surgery 34 43.8 (27.0–60.5) 10 (2–24) 0–60
CI, conﬁdence interval; mBCC, metastatic basal cell carcinoma; NE, not evaluable.
a Between-group comparison of overall survival data.
Fig. 1. Survival after metastatic basal cell carcinoma (mBCC) diagnosis for cases with regional metastases (n = 50) compared with distant
metastases (n = 50). NE, not evaluable.
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88 months; P = 0.026). However, 14 of 24 (58%) cases
with bone metastases had disease spread to two or more
sites, compared with only seven of 26 (27%) cases with-
out bone metastases.
Median survival was signiﬁcantly longer among 28
DM cases with lung metastases than in 22 DM cases
without lung metastases: 66 months (95% CI, 24–
76 months) versus 10 months (95% CI, 3–24 months;
P = 0.0002). For these cases, 12 of 28 (43%) with lung
metastases had disease spread to two or more sites, com-
pared with nine of 22 (41%) cases without lung metasta-
ses. Kaplan–Meier analyses that compared survival by
number of metastatic sites (less than two versus two or
more), age (<65 versus P65 years), sex and publicationyear (1981–1990 versus 1991–2000 versus 2001–2011)
did not identify any signiﬁcant survival diﬀerences (data
not shown).
4. Discussion
This analysis provides a comprehensive description of
the mBCC disease course and survival based on 100
cases reported in the peer-reviewed literature from
1981 to 2011. Based on total known follow-up times
for the mBCC cases included in this analysis, Kaplan–
Meier estimates of the median mBCC survival times
were 24 months for DM cases and 87 months for RM.
Previously reported median mBCC survival times
ranged from 8 to 14 months; however, these were not
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have been restricted to patients who died, resulting in
shorter median survival times [5,6,97]. In contrast, a
recent retrospective Kaplan–Meier analysis of 10 cases
from a single institution reported considerably longer
mBCC survival than previously published estimates
[98]. This analysis included cases with distant mBCC
but excluded metastases with basosquamous histology,
which are currently categorised in the National Compre-
hensive Cancer Network (NCCN) guidelines as squa-
mous cell carcinoma because of a more aggressive
clinical course [99].
The observed association between mBCC survival
time and metastasis location is consistent with prior
reports of longer survival among cases with lymphatic
versus haematogenous spread [100]. RM cases had both
a higher 1-year survival probability and a longer median
survival time than DM cases. The survival times calcu-
lated with the extent of disease-based categories are sim-
ilar to those observed in survival analyses based on
lymph node–only versus non-lymph node metastases
and support the use of current tumour staging systems
to characterise mBCC cases [101]. The eﬀect of treat-
ment on survival could not be assessed because treat-
ment choice depended on extent of disease spread (ie,
chemotherapy for DM, surgery for RM) and the small
number of cases in this analysis precluded use of multi-
variate methods.
Overall, 38 mBCC cases (ﬁve RM and 33 DM) were
reported to have died of disease. Cause of death was
related to complications of disease or treatment, such
as cachexia, pneumonia and renal failure. Among RM
cases who died, ﬁve of 13 cases (38.5%) died of disease
compared with 33 of 35 (94.3%) of DM cases. This dif-
ference is consistent with the shorter survival time
among DM cases observed in the survival analysis and
the expectation that DM cases had mBCC-speciﬁc
deaths.
Among DM cases, patients with bone metastases
seemed to have signiﬁcantly shorter survival times than
those without bone metastases. In contrast, patients
with lung metastases seemed to have signiﬁcantly longer
survival times than those without lung metastases. These
ﬁndings suggest that longer survival may be more clo-
sely related to metastasis site than to overall disease bur-
den. Further study is needed to evaluate whether these
observations are valid.
Among all 100 mBCC cases, nine had spread to three
or more sites, which made it diﬃcult to evaluate the
number of metastatic sites as an independent predictor
of survival. When these nine cases were compared with
91 cases with metastases to two or fewer sites, the diﬀer-
ence in median survival was not statistically signiﬁcant.
Larger case series or data from population-based
sources may provide more eﬀective evaluation of the
association between disease burden and survival.Because mBCC is rare and limited information about
the disease has been reported, it can be diﬃcult to con-
ﬁrm that a case is truly mBCC as opposed to a second
primary skin BCC or a diﬀerent tumour type altogether.
To address this issue, cases described as basaloid carci-
nomas in organs other than skin were excluded.
Although we were limited to the author assessment of
the tumours, the majority of authors justiﬁed the mBCC
diagnosis based on the Lattes and Kessler [7] criteria,
which require documented history of a prior BCC of
skin and histological conﬁrmation of metastasis. Several
recent case reports used immunohistochemistry to con-
ﬁrm mBCC diagnosis by ruling out other tumour types
as the source of metastasis [4,10,22,28]. In addition, one
study reported an association between trisomy 6 and
mBCC [31]. However, no immunohistochemical or
molecular markers have emerged that reliably predict
which BCCs are more likely to metastasise or that inde-
pendently conﬁrm mBCC diagnoses, and the cases
included in this analysis did not contain information
on the mutational status of the BCCs.
It was diﬃcult to determine whether the histology of
the primary and metastatic lesions was identical because
most cases did not have speciﬁc descriptions for both.
However, 31 cases had identical histology subtype
descriptions for primary and metastatic lesions.
Although we cannot conﬁrm that the primary tumours
described for cases included in this analysis were the
actual source of the mBCC, the high proportion of cases
with consistent histology descriptions among those that
reported this information is reassuring. Only 10% of
cases included in this analysis were described as being
of a basosquamous or a metatypical subtype. While
there is widespread belief that basosquamous BCCs
are much more likely to metastasise, the data show that
other histology subtypes also lead to mBCC.
Overall, the data reveal considerable variation in how
mBCC cases are treated, which is consistent with the
lack of treatment standards for this disease. Surgery
and radiation therapy were the most commonly
reported treatments for RM and DM cases. The higher
proportion of RM cases treated with surgery and radia-
tion therapy suggests that these treatments might have
been oﬀered with curative intent for this earlier stage
of disease. Only 20 of 100 mBCC cases included in this
analysis, of which 17 were DM cases, received chemo-
therapy to treat their metastases. Although DM cases
were more likely than RM cases to receive chemother-
apy, DM cases were also more likely to receive no treat-
ment at all.
Among the 20 cases described in this report who were
treated with chemotherapy, 16 (80%) received platinum-
based agents and six of 16 (38%) had a favourable
response to therapy. In other words, there was no evi-
dence of disease or partial response after treatment. This
ﬁnding is consistent with publications that describe
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However, there are no randomised clinical trials that
measure survival beneﬁt or impact on quality of life
for these agents in this setting [3,102].
A few limitations should be considered when inter-
preting the results of this analysis. First, case reports
published in the literature might represent the extremes
of what is seen in typical clinical practice. In other
words, cases with unusually short or long survival times
might be more likely to be reported. Second, this analy-
sis is based on information reported in published articles
and, therefore, depends on the authors’ clinical judg-
ment and stated diagnoses. Several cases were excluded
because they lacked information on survival time after
mBCC diagnosis. In addition, some included cases were
eventually lost to follow-up or were reported shortly
after mBCC diagnosis, with minimal follow-up time.
Finally, these data are retrospective and should be used
only to generate hypotheses for further study.
Because mBCC is rare, some clinicians might be una-
ware that BCC can metastasise and might not recognise
or correctly diagnose the disease. Therefore, although
the ﬁndings from this analysis are consistent with previ-
ously published estimates that report survival diﬀerences
based on site of disease spread, we cannot fully validate
these results. Moreover, this analysis is limited by its
small sample size and retrospective nature. Analyses of
population-based data sources or prospective observa-
tional studies could provide more insight into the natu-
ral history of mBCC.
Theoretically, changes in mBCC treatment patterns
and overall improvement in health care quality over
time may have also aﬀected survival. However, compar-
ison of median survival among cases reported in 1981–
1990, 1991–2000 and 2001–2011 did not demonstrate a
signiﬁcant survival diﬀerence between these periods,
and there was no apparent trend over time. New treat-
ments for mBCC are now being introduced. This article
provides information on cases that were described
before the introduction of new therapies and, therefore,
can serve as a benchmark for the eﬀect of these new
treatments.
Until recently, no approved therapies for mBCC were
available [8]. During a time when new treatment options
are emerging, this study provides a comprehensive,
updated assessment of the disease course and survival
diﬀerences based on site of spread for mBCC, and the
historical context of this disease.
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